Neovacs is strategically advised by a distinguished board of directors made up of six experienced members with varied professional backgrounds, two of which are independent directors.
Hugo Brugière
Chairman and CEO
Hugo is a graduate of the Saint-Cyr Special Military School and SciencesPo Paris. A serial entrepreneur with more than twenty companies to his credit, he has specialized for several years in stock market and restructuring/turnaround with listed companies.
Current Chairman and CEO of Neovacs, Hugo also exercises numerous mandates in different companies in France and around the world (ARCTURUS GROUP, BISTROTS PAS PARISIENS, CYBERGUN, KEYMEX, etc.).
Former general delegate of the Employers' Organization of Accountants and Auditors, he has also served several prominent political figures. As Reserve Officer, he commanded a company in the 19th Engineer Regiment of Besançon.
The companies he manages today have approximately 700 employees for an overall turnover of nearly 60 million euros.
Jean-Jacques Bertrand
Member of the board
Graduated from the École des Hautes Etudes Commerciales in Paris, Jean-Jacques Bertrand worked at the Rhône Poulenc group in 1965. As Chairman of Theraplix and Specia, he took over the General Management of Pharmaceutical Operations of Rhône Poulenc Monde in 1987.
He was appointed CEO of Rhône Poulenc Rorer in 1990, CEO of Avantis Pasteur from 1994 to 2003, and additionally was chair of the Pharmaceutical Industry Syndicate in 2000-2001. From 2006 to 2013, he was chair of Guerbet Board of Directors and of Pierre-Fabre SA from 2013 to 2017, the latter of which he remains a manager today.
Daniel Zagury, MD, PhD
Neovacs Founder
Professor Daniel Zagury, one of the most eminent French immunologists, created Neovacs in 1993 as a spin-off from Pierre and Marie Curie University.
Doctor of Medicine, Doctor of Sciences, and associate of the Faculties of Medicine hospital biologist (competition 1966), Daniel Zagury has a career as a teacher-researcher and physician. He founded Neovacs, a spin-off of the University Pierre and Marie Curie Paris, while he was head of the Department of Cellular Physiology at this University. He worked as an Associate Professor of Anatomy at Columbia University (1966-1967), as Professor of Histology, Embryology and Cytogenetics at the Faculty of Medicine of Reims (1967-1976), as Professor of Cellular Physiology (1977-1995), and Scientific Director of the DEA (Immunobiotechnology, Immunogenetics and Blood Transfusion) at the Pierre & Marie Curie University (1980-1988). As a physician, he directed the Cytology and Immunology laboratory of the Jean Godinot anti-cancer Center (Reims, 1967-1992). During his research career, he has published more than 150 articles in international journals including Nature, Science and PNAS. Daniel Zagury has developed toxoid and Kinoid vaccines. He is co-inventor of 14 patents relating the concept and manufacturing processes of these immunogenic molecules for therapeutic purposes.
Monsieur Baudouin Hallo
Member of the board
A graduate of Ecole Centrale Paris and of Sciences Po Paris with a double degree in Environmental Sciences and Policies, Baudouin Hallo began his career in management consulting, particularly working on business transformation missions, support for general management and project management. At the same time, at the age of 24, he created his first company which specialized in the preparation of post-Bac exams. Today, as Managing Director of the HBR Investment Group fund, he is a member of several Boards of Directors within the group's holdings. He is also Deputy CEO of Cybergun SA with Hugo Brugière. Manager of several companies such as Restarted Investment, he actively contributed to the Grand Prix Restructuring 2015 for Cybergun SA, which was awarded the most emblematic restructuring operation of the year.
Madame Muriel Haim
Member of the board
Muriel Haim is Doctor of Medicine, holder of a Master in communication and a postgraduate degree in health economics at the University of Paris Dauphine. She practiced in a private office, and then joined the pharmaceutical industry where she worked as a Communication Manager between France and the United States for Sanofi in the health branch before creating the Department of Health Economics. In the United States, Ms. Haim joined Merck & Co where as V.P. of Outcome Research WorldWide she was in charge of pricing and reimbursement strategies.
Currently Muriel Haim is a consultant for the pharmaceutical industry.